ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 7, 2020

9:00AM-11:00AM: Abstract Number: 0657

Gout and Heart Failure in the US

Metabolic & Crystal Arthropathies Poster

9:00AM-11:00AM: Abstract Number: 0681

Gout and Serum Urate Levels Are Associated with Lumbar Spine Monosodium Urate Deposition and Chronic Low Back Pain: A Dual-Energy CT Study

Metabolic & Crystal Arthropathies Poster

9:00AM-11:00AM: Abstract Number: 0600

Gout Increases Length of Stay in Patients Hospitalized for Heart Failure Exacerbation

Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 0673

Gout Is an Independent Risk Factor for Undergoing an Amputation Procedure

Metabolic & Crystal Arthropathies Poster

9:00AM-11:00AM: Abstract Number: 0667

Gout Management Beyond Prescription Writing: The Role of the Pharmacist

Metabolic & Crystal Arthropathies Poster

9:00AM-11:00AM: Abstract Number: 0853

Gradual Glucocorticoid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus

SLE – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0888

Guselkumab Efficacy and Safety in TNF-Inhibitor-Experienced and TNF-Inhibitor-Naïve Patients with Active PsA: 1-Year Results of a Phase 3, Randomized, Controlled Study

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0908

Guselkumab Efficacy in Adult Patients with Active Psoriatic Arthritis by Baseline Demographic and Disease Characteristics: Pooled Results of Two Phase 3, Randomized, Placebo-Controlled Studies

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0746

HDL-bound yRNA-derived Small RNAs Are Altered in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster II: Biomarkers

9:00AM-11:00AM: Abstract Number: 0566

Healthcare Utilization and Costs Prior to Diagnosis of ANCA Vasculitis in Medicare Beneficiaries

Epidemiology & Public Health Poster II: OA, Osteoporosis, & Other Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 0845

Hematopoietic Specific Deficiency of Rho Kinase Attenuates Neutrophil NETosis and UVB-induced Skin Inflammation

SLE – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 0849

Herpes Zoster Events with Anifrolumab in Patients with Active SLE: An Integrated Analysis of Phase 2 and Phase 3 Trials

SLE – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0765

High Disease Activity at Baseline and Seropositivity Are Associated with Treatment Response at One Year Post Synovial Biopsy in RA Patients

RA – Diagnosis, Manifestations, & Outcomes Poster II: Biomarkers

9:00AM-11:00AM: Abstract Number: 0820

High Remission Rates in RA – Real Life Data from Bariticinib

RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

9:00AM-11:00AM: Abstract Number: 0595

High Satisfaction with Tele-medicine in a New York City Clinic

Health Services Research Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].